Inebilizumab Disease Interactions
There are 4 disease interactions with inebilizumab.
Inebilizumab (applies to inebilizumab) hepatitis B
Major Potential Hazard, Moderate plausibility. Applicable conditions: Infectious Hepatitis
The use of inebilizumab is contraindicated in patients with active hepatitis B infection.
Inebilizumab (applies to inebilizumab) tuberculosis
Major Potential Hazard, Moderate plausibility. Applicable conditions: Tuberculosis -- Active, Tuberculosis -- Latent
The use of inebilizumab is contraindicated in patients with active or untreated latent tuberculosis.
Inebilizumab (applies to inebilizumab) infections
Moderate Potential Hazard, Moderate plausibility. Applicable conditions: Infection - Bacterial/Fungal/Protozoal/Viral
An increased risk of infections has been observed with the use of inebilizumab. It is recommended to delay administration in patients with an active infection until the infection is resolved. Perform HBV screening in all patients before initiation of treatment. Do not administer this agent to patients with active hepatitis. Patients should be evaluated for tuberculosis risk factors and tested for latent infection prior to initiating treatment. Consider anti-tuberculosis therapy in patients with a history of latent active tuberculosis in whom an adequate course of treatment cannot be confirmed, and for patients with a negative test for latent tuberculosis but having risk factors for tuberculosis infection. Consult infectious disease experts regarding whether initiating therapy is appropriate before starting treatment.
Inebilizumab (applies to inebilizumab) vaccination
Moderate Potential Hazard, Moderate plausibility.
The use of live attenuated-vaccines or live vaccines is not recommended during treatment with inebilizumab until B-cell repletion. Administer all required immunizations at least 4 weeks prior to initiation of inebilizumab. The safety of immunization with live or live-attenuated vaccines following inebilizumab therapy has not been studied, therefore it is not recommended during treatment until B-cell repletion. Do not administer live or live-attenuated vaccines to infants of mothers exposed to inebilizumab during pregnancy before confirming recovery of B-cell counts. Non-live vaccines, may be administered prior to recovery from B-cell and immunoglobulin level depletion, but to assess whether a protective immune response was mounted, consultation with a qualified specialist should be considered.
Switch to professional interaction data
Inebilizumab drug interactions
There are 160 drug interactions with inebilizumab.
Report options
More about inebilizumab
- inebilizumab consumer information
- Check interactions
- Compare alternatives
- Side effects
- Dosage information
- During pregnancy
- Drug class: selective immunosuppressants
- En español
Related treatment guides
Drug Interaction Classification
| Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. | |
| Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. | |
| Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. | |
| No interaction information available. |
See also:
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
